Skip to content

Commit 4c88d88

Browse files
authored
Merge pull request #369 from monarch-initiative/pr/atopic-dermatitis-beta-thalassemia-curation
Add curated Atopic Dermatitis and Beta Thalassemia disorder entries
2 parents b5dabe2 + f5cb9f7 commit 4c88d88

File tree

2 files changed

+1112
-0
lines changed

2 files changed

+1112
-0
lines changed
Lines changed: 395 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,395 @@
1+
name: Atopic Dermatitis
2+
category: Complex
3+
parents:
4+
- Dermatological Disease
5+
- Chronic Inflammatory Disease
6+
- Allergic Disease
7+
has_subtypes:
8+
- name: Early-Onset Atopic Dermatitis
9+
description: Onset in infancy or early childhood, often associated with the
10+
atopic march progressing to asthma and allergic rhinitis.
11+
- name: Adult-Onset Atopic Dermatitis
12+
description: First presentation in adulthood, often with different clinical
13+
distribution and associations compared to childhood-onset disease.
14+
- name: Extrinsic Atopic Dermatitis
15+
description: Associated with IgE-mediated sensitization to environmental
16+
allergens. Elevated serum IgE and positive skin prick tests.
17+
- name: Intrinsic Atopic Dermatitis
18+
description: Without IgE-mediated sensitization. Normal serum IgE levels.
19+
Represents approximately 20% of cases.
20+
pathophysiology:
21+
- name: Epidermal Barrier Dysfunction
22+
description: Loss-of-function mutations in filaggrin (FLG) and other barrier
23+
proteins lead to impaired skin barrier integrity, increased transepidermal
24+
water loss, and enhanced allergen penetration. This is the primary
25+
initiating event in many patients.
26+
genes:
27+
- preferred_term: FLG
28+
term:
29+
id: hgnc:3748
30+
label: FLG
31+
biological_processes:
32+
- preferred_term: Keratinization
33+
term:
34+
id: GO:0031424
35+
label: keratinization
36+
cell_types:
37+
- preferred_term: Keratinocyte
38+
term:
39+
id: CL:0000312
40+
label: keratinocyte
41+
evidence:
42+
- reference: PMID:16550169
43+
supports: SUPPORT
44+
evidence_source: HUMAN_CLINICAL
45+
snippet: Filaggrin is a key protein that facilitates terminal
46+
differentiation of the epidermis and formation of the skin barrier. Here
47+
we show that two independent loss-of-function genetic variants (R510X
48+
[sic, correct designation is R501X] and 2282del4) in the gene encoding
49+
filaggrin (FLG) are very strong predisposing factors for atopic
50+
dermatitis.
51+
explanation: Landmark study establishing FLG loss-of-function as the
52+
strongest genetic risk factor for atopic dermatitis, with ~9% carrier
53+
frequency in Europeans.
54+
- reference: PMID:21388665
55+
supports: PARTIAL
56+
evidence_source: HUMAN_CLINICAL
57+
snippet: They are similar in that they are complex inherited diseases
58+
involving genes that encode immune components and structural proteins that
59+
regulate differentiation of epidermal cells. Each disease is characterized
60+
by proliferation of epidermal keratinocytes and abnormal cornification or
61+
terminal differentiation in the epidermis
62+
explanation: Describes the epidermal barrier dysfunction in atopic
63+
dermatitis including abnormal cornification and keratinocyte
64+
differentiation.
65+
- name: Type 2 Immune Response
66+
description: Th2-skewed immune response drives the hallmark inflammation.
67+
IL-4, IL-13, and IL-31 promote IgE production, eosinophil recruitment, and
68+
pruritus. IL-4/IL-13 signaling through JAK1/STAT6 further impairs barrier
69+
function by downregulating filaggrin and other barrier proteins.
70+
genes:
71+
- preferred_term: IL4
72+
term:
73+
id: hgnc:6014
74+
label: IL4
75+
- preferred_term: IL13
76+
term:
77+
id: hgnc:5973
78+
label: IL13
79+
- preferred_term: IL31
80+
term:
81+
id: hgnc:19372
82+
label: IL31
83+
- preferred_term: STAT6
84+
term:
85+
id: hgnc:11368
86+
label: STAT6
87+
downstream:
88+
- target: Epidermal Barrier Dysfunction
89+
description: IL-4 and IL-13 downregulate filaggrin expression, creating a
90+
vicious cycle of barrier disruption and immune activation.
91+
- target: Pruritogen-Induced Neuronal Activation
92+
description: IL-31 signaling contributes to neuronal itch signaling in
93+
lesional skin.
94+
biological_processes:
95+
- preferred_term: Type 2 immune response
96+
term:
97+
id: GO:0042092
98+
label: type 2 immune response
99+
- preferred_term: T-helper 2 cell differentiation
100+
term:
101+
id: GO:0045064
102+
label: T-helper 2 cell differentiation
103+
- preferred_term: Interleukin-4-mediated signaling pathway
104+
term:
105+
id: GO:0035771
106+
label: interleukin-4-mediated signaling pathway
107+
- preferred_term: IgE isotype switching
108+
term:
109+
id: GO:0035708
110+
label: interleukin-4-dependent isotype switching to IgE isotypes
111+
cell_types:
112+
- preferred_term: T-helper 2 cell
113+
term:
114+
id: CL:0000546
115+
label: T-helper 2 cell
116+
- preferred_term: Group 2 innate lymphoid cell
117+
term:
118+
id: CL:0001069
119+
label: group 2 innate lymphoid cell
120+
- preferred_term: Eosinophil
121+
term:
122+
id: CL:0000771
123+
label: eosinophil
124+
- preferred_term: Mast cell
125+
term:
126+
id: CL:0000097
127+
label: mast cell
128+
evidence:
129+
- reference: PMID:30819278
130+
supports: SUPPORT
131+
evidence_source: HUMAN_CLINICAL
132+
snippet: Type 2 cytokines as well as interleukin 17 and interleukin 22
133+
contribute to skin barrier dysfunction and the development of AD.
134+
explanation: Confirms the role of type 2 cytokines in AD pathophysiology and
135+
their contribution to barrier dysfunction, supporting the Th2/type 2
136+
immune mechanism.
137+
- reference: PMID:21388665
138+
supports: PARTIAL
139+
evidence_source: HUMAN_CLINICAL
140+
snippet: skin lesions contain immune infiltrates of T cells, dendritic
141+
cells, and other types of leukocytes. We review similarities between the
142+
diseases and differences in epidermal barrier defects and immune cells.
143+
explanation: Describes the immune cell infiltrates in AD lesions including T
144+
cells and dendritic cells, consistent with type 2 immune response.
145+
- name: Th17/Th22 Inflammation
146+
description: In addition to the dominant Th2 response, Th17 and Th22 cells
147+
contribute to inflammation, particularly in acute lesions and Asian
148+
patients. IL-17 and IL-22 further disrupt epidermal differentiation.
149+
biological_processes:
150+
- preferred_term: T-helper 17 type immune response
151+
term:
152+
id: GO:0072538
153+
label: T-helper 17 type immune response
154+
cell_types:
155+
- preferred_term: T-helper 17 cell
156+
term:
157+
id: CL:0000899
158+
label: T-helper 17 cell
159+
- name: Pruritogen-Induced Neuronal Activation
160+
description: IL-31 and other pruritogens activate cutaneous sensory neurons,
161+
generating persistent itch in atopic dermatitis.
162+
genes:
163+
- preferred_term: IL31
164+
term:
165+
id: hgnc:19372
166+
label: IL31
167+
downstream:
168+
- target: Scratching-Induced Barrier Injury
169+
description: Persistent itch drives repetitive scratching behavior.
170+
cell_types:
171+
- preferred_term: Sensory neuron
172+
term:
173+
id: CL:0000101
174+
label: sensory neuron
175+
evidence:
176+
- reference: PMID:30819278
177+
supports: PARTIAL
178+
evidence_source: HUMAN_CLINICAL
179+
snippet: New insights into the pathophysiology of AD have focused on
180+
epidermal lipid profiles, neuroimmune interactions, and microbial
181+
dysbiosis.
182+
explanation: Supports neuroimmune signaling as a component of AD
183+
pathophysiology.
184+
- name: Scratching-Induced Barrier Injury
185+
description: Repetitive scratching causes mechanical skin injury and worsens
186+
epidermal barrier dysfunction.
187+
downstream:
188+
- target: Secondary Inflammatory Amplification
189+
description: Mechanical barrier injury increases local inflammatory
190+
activation.
191+
cell_types:
192+
- preferred_term: Keratinocyte
193+
term:
194+
id: CL:0000312
195+
label: keratinocyte
196+
- name: Secondary Inflammatory Amplification
197+
description: Barrier injury from scratching perpetuates inflammatory signaling
198+
and contributes to chronic lesion persistence.
199+
biological_processes:
200+
- preferred_term: Inflammatory response
201+
term:
202+
id: GO:0006954
203+
label: inflammatory response
204+
cell_types:
205+
- preferred_term: Keratinocyte
206+
term:
207+
id: CL:0000312
208+
label: keratinocyte
209+
phenotypes:
210+
- name: Eczematoid Dermatitis
211+
category: Dermatological
212+
frequency: VERY_FREQUENT
213+
diagnostic: true
214+
notes: Erythematous, pruritic patches and plaques with scaling, often in
215+
flexural areas.
216+
phenotype_term:
217+
preferred_term: Eczematoid dermatitis
218+
term:
219+
id: HP:0000964
220+
label: Eczematoid dermatitis
221+
- name: Pruritus
222+
category: Dermatological
223+
frequency: VERY_FREQUENT
224+
diagnostic: true
225+
notes: Intense itching is the hallmark symptom, often worse at night.
226+
phenotype_term:
227+
preferred_term: Pruritus
228+
term:
229+
id: HP:0000989
230+
label: Pruritus
231+
- name: Xerosis
232+
category: Dermatological
233+
frequency: VERY_FREQUENT
234+
notes: Generalized dry skin reflecting barrier dysfunction.
235+
phenotype_term:
236+
preferred_term: Xerosis
237+
term:
238+
id: HP:0000958
239+
label: Dry skin
240+
- name: Lichenification
241+
category: Dermatological
242+
frequency: FREQUENT
243+
notes: Thickened, leathery skin from chronic scratching.
244+
phenotype_term:
245+
preferred_term: Lichenification
246+
term:
247+
id: HP:0100725
248+
label: Lichenification
249+
- name: Elevated Serum IgE
250+
category: Immunological
251+
frequency: FREQUENT
252+
notes: Present in extrinsic subtype (~80% of patients).
253+
phenotype_term:
254+
preferred_term: Elevated serum IgE
255+
term:
256+
id: HP:0003212
257+
label: Increased circulating IgE concentration
258+
genetic:
259+
- name: FLG
260+
association: Associated
261+
notes: Loss-of-function variants are the strongest genetic risk factor. R501X
262+
and 2282del4 are common in European populations.
263+
evidence:
264+
- reference: PMID:16550169
265+
supports: SUPPORT
266+
evidence_source: HUMAN_CLINICAL
267+
snippet: two independent loss-of-function genetic variants (R510X
268+
[sic, correct designation is R501X] and 2282del4) in the gene encoding
269+
filaggrin (FLG) are very strong predisposing factors for atopic
270+
dermatitis. These variants are carried by approximately 9% of people of
271+
European origin.
272+
explanation: Landmark Palmer et al. 2006 study establishing FLG
273+
loss-of-function as the major genetic predisposing factor for atopic
274+
dermatitis.
275+
- name: IL4R
276+
association: Associated
277+
notes: Variants in IL-4 receptor alpha chain affect Th2 signaling intensity.
278+
- name: IL13
279+
association: Associated
280+
notes: Variants affecting IL-13 expression or function.
281+
- name: STAT6
282+
association: Associated
283+
notes: Transcription factor downstream of IL-4/IL-13 signaling.
284+
- name: EMSY
285+
association: Associated
286+
notes: Chromatin remodeling factor identified in GWAS.
287+
- name: BACH2
288+
association: GWAS
289+
notes: Transcription factor regulating Treg/effector T cell balance and B cell
290+
class switching
291+
- name: TNFAIP3
292+
association: GWAS
293+
notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB
294+
signaling
295+
- name: EGR2
296+
association: GWAS
297+
notes: Transcription factor involved in T cell anergy and peripheral tolerance
298+
- name: ETS1
299+
association: GWAS
300+
notes: Transcription factor regulating T and B cell development and immune
301+
cell differentiation
302+
- name: IRF4
303+
association: GWAS
304+
notes: Transcription factor essential for Th17 and Th2 cell differentiation
305+
and plasma cell development
306+
- name: SATB1
307+
association: GWAS
308+
notes: Chromatin organizer regulating T cell development and lineage
309+
commitment
310+
- name: SMAD3
311+
association: GWAS
312+
notes: TGF-beta signaling mediator regulating T cell differentiation and
313+
immune tolerance
314+
- name: REL
315+
association: GWAS
316+
notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
317+
environmental:
318+
- name: Allergen Exposure
319+
description: House dust mites, pet dander, and pollens can trigger or
320+
exacerbate disease.
321+
effect: TRIGGERS
322+
- name: Skin Irritants
323+
description: Soaps, detergents, and harsh fabrics disrupt the already
324+
compromised barrier.
325+
effect: TRIGGERS
326+
- name: Microbial Dysbiosis
327+
description: Staphylococcus aureus colonization is found in >90% of lesional
328+
skin and amplifies inflammation through superantigens and biofilm formation.
329+
effect: WORSENS
330+
treatments:
331+
- name: Emollients and Moisturizers
332+
description: First-line treatment to restore skin barrier function and reduce
333+
transepidermal water loss.
334+
- name: Topical Corticosteroids
335+
description: First-line anti-inflammatory treatment for flares, applied to
336+
affected areas.
337+
- name: Dupilumab
338+
description: Monoclonal antibody targeting IL-4 receptor alpha, blocking both
339+
IL-4 and IL-13 signaling. FDA-approved for moderate-to-severe atopic
340+
dermatitis.
341+
treatment_term:
342+
preferred_term: pharmacotherapy
343+
term:
344+
id: MAXO:0000058
345+
label: pharmacotherapy
346+
- name: JAK Inhibitors
347+
description: Oral (baricitinib, upadacitinib, abrocitinib) and topical
348+
(ruxolitinib) JAK inhibitors targeting the JAK-STAT pathway downstream of
349+
type 2 cytokines.
350+
treatment_term:
351+
preferred_term: pharmacotherapy
352+
term:
353+
id: MAXO:0000058
354+
label: pharmacotherapy
355+
- name: Phototherapy
356+
description: Narrowband UVB phototherapy for moderate-to-severe disease.
357+
disease_term:
358+
preferred_term: atopic dermatitis
359+
term:
360+
id: MONDO:0004980
361+
label: atopic eczema
362+
references:
363+
- reference: DOI:10.1007/s13555-025-01352-y
364+
title: 'Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review'
365+
findings: []
366+
- reference: DOI:10.1038/s41467-023-41857-8
367+
title: Multifaceted analysis of cross-tissue transcriptomes reveals
368+
phenotype–endotype associations in atopic dermatitis
369+
findings: []
370+
- reference: DOI:10.1126/sciimmunol.abi6887
371+
title: IL-31–dependent neurogenic inflammation restrains cutaneous type 2
372+
immune response in allergic dermatitis
373+
findings: []
374+
- reference: DOI:10.1186/s43556-025-00313-3
375+
title: 'Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics'
376+
findings: []
377+
- reference: DOI:10.14789/ejmj.jmj24-0036-r
378+
title: Mechanisms of Itch in Atopic Dermatitis
379+
findings: []
380+
- reference: DOI:10.3390/jcm12041538
381+
title: 'The Role of Tight Junctions in Atopic Dermatitis: A Systematic Review'
382+
findings: []
383+
- reference: DOI:10.3390/jcm14145053
384+
title: 'Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted
385+
Treatment'
386+
findings: []
387+
- reference: DOI:10.64898/2026.01.10.26343854
388+
title: 'Protective and Susceptibility Clusters of Environmental Factors, Gene Expression,
389+
Antibody Responses, and Cytokines in Pediatric Atopic Dermatitis: Insights from
390+
Multi-Modal Data Integration'
391+
findings: []
392+
- reference: DOI:10.7759/cureus.86937
393+
title: 'Skin Barrier Dysfunction in Chronic Dermatoses: From Pathophysiology to
394+
Emerging Therapeutic Strategies'
395+
findings: []

0 commit comments

Comments
 (0)